The remainder of this review will focus on elucidating some of the principal strategies available for targeting CXCL8-CXCR1/2 signaling in cancer, both indirectly with the use of anti-inflammatories, and directly, using CXCL8- or CXCR1/2-targeted inhibitors. This evidence concerns the gene CXCR1 and cancer.